These studies present autophagy inhibitors as a potential approach to ESCC therapy in patients with RAD51 upregulation; however, additional preclinical studies are necessary to further investigate the efficacy of such an approach. The gene discussed is RAD51; the disease is esophageal squamous cell carcinoma.